1 Interplay between polygenic effects and polypharmacy

2 on dementia: An investigation in an elderly Scottish

3 cohort.

- 4 Vasilis Raptis^{1,2†}, Donncha Mullin^{3,5}, Sumbul Syed⁶, Ian J Deary^{4,7}, Simon R
- 5 Cox^{4,7}, Tom C Russ^{3,5,7}, Michelle Luciano⁴
- 6
- 7 ¹The Roslin Institute, College of Medicine and Veterinary Medicine, University of
- 8 Edinburgh
- 9 ²Advanced Care Research Centre, School of Engineering, University of
- 10 Edinburgh
- ¹¹ ³Alzheimer Scotland Dementia Research Centre, University of Edinburgh
- 12 ⁴Department of Psychology, University of Edinburgh
- ¹³ ⁵Division of Psychiatry, Centre for Clinical Brain Sciences, University of
- 14 Edinburgh
- ¹⁵ ⁶School of Health in Social Science, University of Edinburgh
- ¹⁶ ⁷Lothian Birth Cohorts, University of Edinburgh
- 17
- ¹⁸ [†] Corresponding author:
- 19 Vasilis Raptis
- 20 e-mail: V.Raptis@sms.ed.ac.uk

21

22 ABSTRACT

INTRODUCTION: Polygenic Risk Scores for Alzheimer dementia (AD-PRS), a
 measure of aggregate AD genetic risk and polypharmacy have been associated
 with dementia. Here, we test their interaction's association with future dementia
 among older adults without baseline neurodegenerative diagnoses.

METHODS: Using Cox proportional hazards and mortality-adjusted competing risk regression models we analysed up to 17.5 years all-cause incident dementia in the Lothian Birth Cohort 1936 (n=759, 105 dementia patients). We used polypharmacy (total or nervous-system-acting medications count), AD-PRS, and their interaction as main predictors.

RESULTS: A non-significant interaction was found between AD-PRS and total polypharmacy (HR=1.06; p=0.15) or nervous-system-acting polypharmacy (HR=0.98; p=0.86) in shaping dementia risk. Omitting interaction, mortalityadjusted models showed significant AD-PRS prediction of dementia (HR ~1.40; p<0.001), non-significant total (HR=1.03; p=0.49), and nervous-system-acting polypharmacy effects (HR=1.27; p=0.069).

38 DISCUSSION: Elucidating the complex interplay between polypharmacy and 39 genetics could improve management of inappropriate medication in older adults 40 genetically prone to dementia/AD.

41

42 KEYWORDS: Alzheimer dementia, dementia, polygenic risk score,
43 polypharmacy, longitudinal study, gene-environment interaction

44

45 **1 BACKGROUND**

Dementia, a condition describing the significant and progressive overall deterioration of a person's cognition with consequent deterioration in function¹, is widely recognised to have multi-factorial causes, arising from the interplay between environmental, lifestyle and genetic factors^{2,3}.

50 Alzheimer dementia (AD), the most frequent cause of dementia (accounting for 51 70 - 80% of dementia⁴) has been extensively shown to have a strong genetic component⁵⁻⁷. Multiple genetic variants have been identified as risk factors for 52 AD through large-scale Genome-Wide Association Studies (GWAS)^{5,6}. The most 53 unequivocally established AD risk gene is apolipoprotein E (APOE), located on 54 chromosome 19^{8–11}. Its coding protein, Apo-E, is an important cholesterol 55 56 carrying protein, implicated in several brain functions, including lipid transfer, injury repair, neuroinflammation and others. Notably, the APOE $\varepsilon 4$ allele confers 57 a dramatic increase in AD prevalence (4 to 10 fold increase) and lower age of 58 onset⁸, thus being considered an important genetic risk factor for AD. 59

Other smaller effect AD-associated genes have been implicated in multiple biological processes, including microglia involvement, tau and amyloid- β protein metabolism regulation, immunity, inflammation, cholesterol metabolism, and neurotransmitter regulation^{12,13}. To study the contribution of many genetic loci with small effect, Polygenic Risk Scores (PRS) are often implemented, which estimate a single aggregate score for each individual that is indicative of their genetic liability to a disease¹⁴. For AD, PRS calculated using many AD

associated genes have been found in several studies, with varying accuracy, to
be predictive of AD risk, even without including the stronger *APOE* genetic
effect^{5,6,10,11}. Furthermore, AD-PRS have been associated with cognitive
impairment in older healthy adults, as well as several AD related
neurodegeneration phenotypes (e.g. neuroimaging changes)¹².

Although individuals' genetic variation is fixed at birth, genetic effects are thought 72 73 to be modified through their interactions with environmental, lifestyle or social factors throughout life. Such gene by environment (GxE) interactions have been 74 suggested in dementia and AD^{3,15}. Specifically for GxE interactions in dementia, it 75 has been proposed that genetic risk for dementia can be mitigated by favourable 76 modifiable lifestyle factors^{16–18} (i.e., healthy diet, physical activity, non-smoking, 77 78 and low alcohol consumption), although with sometimes conflicting results¹⁷. On the other hand, two randomised clinical trials^{19,20} assessing the effect of 79 80 multidomain lifestyle interventions on dementia found that APOE E4 allele carriers 81 and non-carriers had similar results, indicating no APOE $\varepsilon 4$ interplay with lifestyle factors. However, most studies so far have focused only on APOE genetic 82 variants for GxE interactions^{16,18–20}. 83

Regarding AD-PRS interaction with the environment / lifestyle in shaping dementia or AD risk, less work has been done. In a Chinese cohort study¹⁵, individuals living around higher residential greenness had lower chances of cognitive impairment, with the effect being increased in those having lower PRS genetic risk, although marginally significant. In another study, conducted on a large European cohort, adherence to a healthy lifestyle did not significantly interact with AD PRS in shaping dementia risk².

91 Polypharmacy, a term indicating that someone takes multiple medications, is highly prevalent in older adults with multiple chronic conditions^{21,22}. It has been 92 demonstrated that polypharmacy is associated with unfavourable outcomes, such 93 as increased frequency of falls, increased hospitalisation and hospital 94 readmission, adverse drug reactions and increased mortality^{21,23}. Harmful 95 96 polypharmacy effects may arise due to drug-drug and drug-disease interactions, especially in older people who have a reduced ability to metabolise drugs²⁴. 97 98 Specifically for dementia, the role of polypharmacy as a risk factor is less known²⁵. It has been estimated that polypharmacy burden is higher than the 99 100 general population, given the higher number of comorbid physical conditions in dementia patients^{22,26}, and polypharmacy in people with dementia has been 101 associated with increased emergency hospitalisation and mortality²⁷. 102

Whether the effect of polypharmacy on dementia risk can be modulated by 103 104 genetic factors is not known. In the present study, it is hypothesised that 105 individuals exposed to polypharmacy have an increased dementia risk if they also 106 have a high genetic risk profile, compared to individuals with a low genetic risk 107 profile. This hypothesis is based on the idea that biological pathways which may 108 be disrupted by drug-disease and drug-drug interactions are also affected by the 109 genetic variants that lead to dementia pathology. For example, anticholinergic drugs, acting on acetylcholine neurotransmitters, have been found to increase 110 dementia risk, adverse outcomes, and are frequent in dementia patients with 111 polypharmacy^{22,28}. At the same time, acetylcholine neurotransmission-related 112 genes (e.g. RAB10 gene) have been linked with AD pathogenesis¹³. In this study, 113 114 the proposed hypothesis is addressed in a longitudinal Scottish cohort of older

adults, who were relatively healthy and dementia-free at the baseline age of 70
years. Specifically, an interaction effect between Alzheimer Disease Polygenic
Risk Scores and the number of (1) total and (2) nervous system active baseline
drugs is tested in terms of predicting dementia up to 17.5 years of follow-up.

119

120 2 METHODS

121 **2.1 Dataset description**

122 The present analysis was conducted on the Lothian Birth Cohort 1936 (LBC1936) dataset²⁹. This is a longitudinal study, designed as a follow-up to the Scottish 123 124 Mental Survey of 1947 (SMS1947), an intelligence test conducted on pupils aged 11 years old across Scotland³⁰. From 2004 to 2007, LBC1936 recruited 1,091 125 126 participants of the SMS1947, then aged around 70 years old, and mostly living in Lothian at that time²⁹. Since it focussed on 'normal' cognitive ageing initially, no 127 128 participants had a diagnosis of dementia at baseline. After this first wave of 129 recruitment, participants were re-invited to the study every three years (at mean 130 ages: 73, 76, 79 and 82 years) for follow-up testing, termed Waves 1 to 5 131 respectively. Wave 6 has recently finished, but data is not yet available. At each wave, a wealth of data has been collected from questionnaires, blood tests, 132 133 physical, medical and cognitive measurements. In addition, participants who have 134 consented to do so, have been linked to their electronic health record to obtain 135 further information about their health status (e.g., disease diagnoses, hospital 136 visits). Detailed descriptions of the LBC1936 have been previously reported^{29,31,32}. For this analysis, information from Wave 1 has been utilised, 137

regarding: participants' demographic characteristics, genetic data and selfreported medication usage and medical conditions. The analysis was conducted on 759 individuals (105 dementia patients, 654 controls) for whom complete genetic data (including *APOE* gene alleles) and ascertained dementia outcome as of August 2022 (see "Outcome: incident dementia" section) were available.

143 **2.2 LBC1936 genetic data**

During Wave 1 of the LBC1936, genome-wide genotyping and genotyping of the Apolipoprotein E variants (ϵ_2 , ϵ_3 , and ϵ_4 alleles) was performed^{29,32} for 1,005 individuals. Genotyping of approximately 500,000 genetic variants across the genome (Single Nucleotide Polymorphisms, SNPs) was done using the Illumina Human610-Quadv1 chip³³. Furthermore, non-genotyped variants have been imputed based on the Haplotype Reference Consortium³⁴ reference panel, totalling 39 million SNPs.

High quality SNPs and individuals were extracted, in order to minimise 151 genotyping and imputation errors and reduce the chance of biased results³⁵. The 152 quality control filters applied on genotyped data were described in Houlihan et al, 153 2010³³.I In brief theyincluded the following: One of each related pair of individuals 154 (> 2nd degree relatives, i.e., half-siblings) were excluded (n=8); 1 individual with 155 156 mostly non-European descent was excluded; 12 individuals whose reported and genetically inferred sex did not match (likely indicative of errors during genotype 157 158 sample preparation) were excluded, and; SNPs that were missing from more than 159 2% of the individuals were excluded. For the present analysis, and on the 160 genotyped and imputed data: 4,360,232 SNPs whose alleles were found in a 161 frequency less than 1% in the cohort were excluded: 55 SNPs that deviated

significantly from Hardy-Weinberg Equilibrium were excluded, and; 27.7 million imputed variants with an imputation score less than 0.8 were excluded. These quality control filtering steps were performed using the PLINK(v1.9) software^{36,37}.

799 individuals remained after quality control, containing approximately 7 million
SNPs. 759 individuals formed the final sample for the analysis, after individuals
with missing values in the *APOE* predictor and the covariates were removed (see
below).

169 **2.3 Predictors**

170 2.3.1 Polygenic risk scores

171 Polygenic Risk Scores (PRS) were used as a risk factor representing the 172 aggregated genome-wide genetic effect contributing to AD. PRS are calculated 173 for each individual as a sum of their genome-wide risk alleles, weighted by each allele's effect size to the outcome (here AD status)¹⁴. For AD-PRS calculation, the 174 175 allele effect sizes were obtained from the largest to-date European GWAS on AD, totalling up to 85,934 AD patients (Bellenguez et al, 2022)⁵. AD was chosen, as 176 177 this is the dementia sub-type for which the largest GWAS has been conducted, 178 and the most frequent dementia sub-type in the general population and the 179 present sample (48.6%, Supplementary Table 1).

The PRSice2 (v2.3.5) software³⁸ was used to calculate the AD-PRS. PRSice2 uses the "clumping and thresholding" technique¹⁴. This means that the total number of SNPs is thinned down to retain only SNPs that are independent from each other (clumping) and significantly associated with the outcome (thresholding). Furthermore, the *APOE* region (chromosome 19, base pair

185 44,000,000 to 46,500,000¹¹, in the human reference genome GRCh37 186 coordinates) was removed before the calculation of the AD-PRS (see "*APOE* ε 4 187 alleles" section). Finally, AD-PRS were calculated for the 759 participants with 188 non-missing data, using 981 genome-wide AD associated SNPs at a p-value 189 threshold of < 0.0002.

190 **2.3.2** APOE ε4 alleles

191 Given the strong effect of the APOE $\varepsilon 4$ polymorphisms on dementia, it has been 192 suggested for genomic analyses to treat APOE polymorphisms independently as a separate predictor^{10,11}, as it can mask the effects of other genetic variants with 193 194 weaker effects. The APOE ϵ 4 polymorphism is thus included as a separate risk 195 factor in the present analysis, defined as the number of $\varepsilon 4$ alleles per individual 196 (0, 1 or 2). Since 32 individuals did not have information on APOE status, they 197 have been excluded from the analysis, as this is an important risk factor for 198 dementia.

199 **2.3.3 Polypharmacy**

200 Polypharmacy was defined as the count of total or nervous system-acting drugs 201 taken at baseline. Measurements were obtained using LBC1936 participants' 202 medication data. For each wave of the LBC1936, medication data was based on 203 participants' prescription cards which were brought to the assessment centre and 204 further inspected by the testing team. Data includes prescribed drugs (in their 205 brand name or their generic name), over-the-counter drugs and dietary 206 supplements. To ensure consistency, (e.g., no spelling mistakes, multiple brand 207 names referring to the same drug), we applied several pre-processing steps in

208	order to code each drug name according to the Anatomical Therapeutic
209	Chemical (ATC) classification system ³⁹ . The ATC classification system classifies
210	the active ingredient(s) of a drug in a 5-level hierarchical code, based on its
211	acting organ/anatomical system and its therapeutic, pharmacological, or chemical
212	properties.
213	Specifically, using only medication data from Wave 1 of LBC1936, the pre-
214	processing steps included:
215	• Drugs in their brand names were searched in the British National
216	Formulary (BNF) (<u>https://bnf.nice.org.uk/</u>) ⁴⁰ and substituted with their
217	generic name.
218	• Drugs in their generic name were inspected and corrected for spelling
219	mistakes, also using the BNF website.
220	• Subsequently, for each drug's generic name, its corresponding ATC code
221	was retrieved from the ATC classification system's online searchable
222	database (https://www.whocc.no/atc_ddd_index/) ³⁹ . For drugs with
223	multiple ATC codes (e.g., acting on more than one system), all available
224	ATC codes were retrieved.
225	 The following entries were excluded from the analysis:

- ²²⁶ Drugs that could not be assigned to an ATC code
- o homeopathic substances
- o diet supplements
- o vitamins.
- Additionally, it was deemed appropriate to exclude topically applied
 dermatological drugs and those with ophthalmic, otic or nasal routes of

administration, as they are unlikely to have a systemic effect and interact
with pathways affected by AD related genes.

After these pre-processing steps were applied, a "general" polypharmacy variable was defined as the total number of drugs taken at Wave 1. Additionally, a nervous-system-specific polypharmacy variable was defined as the number of drugs acting on the central nervous system, based on the corresponding ATC code (code starting with "N0" ³⁹).

239 2.3.4 Other covariates

240 Apart from the PRS, APOE and polypharmacy variables, the following variables 241 were included as covariates: sex, age, BMI, Scottish Index of Multiple Deprivation 242 (SIMD) index, smoking status (non-, ex-, or current smoker), alcohol consumption 243 status (yes or no), number of comorbidities (max 10). The number of 244 comorbidities was calculated by summing the presence, at the time of Wave 1 245 assessment, of self-reported diseases among: high blood pressure, diabetes, 246 high cholesterol, history of cardiovascular disease, stroke, neoplasia, arthritis, 247 Parkinson's disease, thyroid disease, leg pain or other unspecified disease. 248 Dates of death were identified via data linkage with the National Health Service 249 Central Register, provided by National Records of Scotland. Participant deaths 250 were flagged to the research team approximately every 12 weeks beginning at 251 study baseline. Finally, to account for any residual genomic population stratification⁴¹, which could inflate the effect of the PRS, the 4 first genomic 252 253 principal components of the individuals were included as covariates.

254 **2.4 Outcome: incident dementia**

In a recent endeavour (as described here^{42,43}), dementia outcomes have been 255 256 ascertained for LBC1936 participants. Briefly, a multi-disciplinary team of clinical dementia experts provided consensus status for dementia and, when possible, 257 dementia sub-types, for all consenting participants⁴². This process included a 258 comprehensive review of participants' electronic health records and death 259 260 certificates for the presence of dementia. Additionally, when deemed necessary, 261 home visits to suspected dementia patients were conducted by a trained clinician. 262 Finally, a consensus diagnostic review board of experts assessed the strength of 263 evidence for each participant, and categorised each as having "probable", 264 "possible", or "no" dementia, as well as each dementia subtype. The dementia 265 and dementia subtype diagnoses were based on the International Classification of Diseases-11 criteria^{42,44}. Furthermore, the age of onset has been reported as 266 267 the earliest age for which any diagnosis was reported. Age of onset spanned a 268 time period from approximately one year after attending Wave 1 attendance until mid-August 2022, when the ascertainment process ended⁴². 269

In the present analysis, only "probable" dementia diagnoses were considered, due to the lack of definite evidence for the assignment of a dementia diagnosis in participants with "possible" dementia⁴². The outcome used here was time-toonset, the time period between Wave 1 assessment until all cause (non-subtype specific) dementia diagnosis in 105 participants.

275 **2.5 Statistical Analysis**

The aim of the present study was to determine the effect of AD-PRS, baseline polypharmacy, and their interaction on incident dementia over up to 17.5 years of follow-up. Given the longitudinal nature of the outcome, Cox proportional hazards

279 (Cox PH) models⁴⁵ were implemented. This type of modelling investigates the 280 association between multiple predictors and the time that passes until an 281 outcome event occurs⁴⁶ (here dementia).

282 In a further analysis, to account for the possible bias of individuals dying before exhibiting the main dementia outcome, the Fine-Gray competing risk model^{47,48} 283 284 was used. This extension of the Cox proportional hazards model estimates the 285 effect of a predictor on the outcome of interest (dementia), given that a competing event has not happened yet (death)⁴⁶. Mirroring the procedure from Mullin et al. 286 (2023)⁴³, for both analyses the time-to-event outcome variables were calculated 287 as the time passing between Wave 1 assessment and the earliest of the 288 289 following: (1) dementia diagnosis, if the individual was ascertained for dementia, 290 (2) the individual's death, if the participant had died while dementia-free, or (3) 291 end of ascertainment, if the individual was dementia-free and alive at the end of 292 the ascertainment period (mid-August 2022). Statistical models were 293 implemented using the predictors described previously ("Predictors" section), as 294 well as the interaction between AD-PRS and the polypharmacy variables. The 295 results of the models are in the form of Hazard Ratios (HR) with 95% confidence 296 intervals (CI) for each tested predictor.

A null model that included only PRS and polypharmacy main effects, without their interaction was also implemented. The statistical analysis for those models was the same as described above.

As a sensitivity analysis, cox PH and competing risk models were also run using time to AD diagnosis as outcome (n=51), as described above for the all-cause dementia models.

All analyses were conducted using the R (v4.2.2) statistical software⁴⁹, and the packages "survival"⁵⁰ for Cox PH models and "cmprsk"⁴⁸ for competing risk models.

306

307 **3 RESULTS**

308 **3.1 Sample characteristics**

309 After genotyping data cleaning and exclusion of individuals with missing values, 310 the analysis sample consisted of 759 individuals. 105 individuals (13.8%) were 311 diagnosed with dementia up to 17.5 years after follow-up from Wave 1. 51 of 312 these individuals (6.7%) had an Alzheimer dementia diagnosis. Participants' 313 characteristics at Wave 1 for all tested covariates are presented in Table 1. 314 Participants' mean age at Wave 1 was 69.5 (standard deviation=0.83) years, 315 while the mean age-at-onset for dementia was 80.7 (3.7) years. The median time 316 from baseline to dementia diagnosis for later patients was 11.8 years 317 [interquartile range (IQR): 7.88-14.35]. 277 (49.5%) participants had passed 318 away at the time of censoring,

Regarding polypharmacy, 164 (21.6%) of participants took 5 to 10 drugs at the time of Wave 1 testing, while 14 (1.8%) took more than 10 drugs simultaneously (excessive polypharmacy) (Sup. Table 2 and Sup. Figure 3), with a maximum of 16 simultaneous drugs. The most abundant drugs by the anatomical system on which they act (according to the ATC classification system³⁹), were those acting on the gastrointestinal system / metabolism (346 individuals taking at least 1, 45.6%), cardiovascular system (388 individuals, 5.1%) and nervous system (321

326	individuals, 42.3%) (Sup. Table 2). In addition, individuals taking multiple
327	medications acting on the same system are reported: 141 (18.6%) individuals
328	taking 3 or more cardiovascular medications; 46 (6 %) individuals taking 3 or
329	more gastrointestinal / metabolic medication; and 9 (1.2%) individuals with 3 or
330	more nervous system active medications simultaneously (Table 1 and Sup. Table
331	2).

1333 TADIE I. DESCRIPTIVE STATISTICS OF LDC 1930 AT WAVE	ave 1.
--	--------

		334	
Variable	Level	Mean (SD) or n (%)	
Sex	Male	392 (51.6) 336	
	Female	368 (48.4)	F
Age (years)		69.5 (0.83) ³³⁷	Footh
BMI (kg/m²)		27.8 (4.24)	- 1
SIMD index		4709 (1836) ³³⁸	ote:
Smoking status	Never	368 (48.5)	
	Ex-Smoker	328 (43.2) 339	DIVII.
	Current	64 (8.4)	Body
Alcohol status	No	99 (13) 540	Douy
	Yes (current)	661 (87) 241	Mass
Comorbidities index		3.1 (1.8)	101233
APOE ε4 count	0	531 (69.9) ₃₄₂	Index.
	1	212 (27.9)	macx,
	2	17 (2.2) ₃₄₃	SD.
No. of drugs		2.9 (2.6)	00.
No. NS-active of drugs		0.51 (0.68) ₃₄₄	stand
Dementia	No	654 (86.2)	o.c.iu
	Yes	105 (13.8) ₃₄₅	ard

deviation; n: number of individuals; SIMD: Scottish Index of Multiple Deprivation; *APOE*: apolipoprotein E gene; NS-active no. of drugs: number of drugs that act
on the nervous system. Polygenic Risk Scores are not reported as they have
mean 0 and sd 1 by default. *SIMD ranges from 4 (most deprived area) to 6505
(least deprived area).

351

353 **3.2 Main analysis**

354 The Cox PH models (unadjusted for death as competing risk) were run using 355 dementia status as the time-to-event outcome variable and polypharmacy 356 (number of drugs), Polygenic Risk Score (PRS) and their interaction (polypharmacy*PRS) as predictors. The models were adjusted for the covariates: 357 358 APOE ε4 count, age, sex, BMI, SIMD index, comorbidities index, alcohol status, 359 smoking status and 4 first genomic principal components. The polypharmacy 360 predictor was either the "general" polypharmacy (total number of drugs) or the 361 nervous system active polypharmacy (number of drugs acting on the nervous system). Cox PH models utilising, among others, age at baseline, sex, 362 363 comorbidities index and socioeconomic variable as predictors of dementia in LBC1936 have been reported by Mullin et al (2023)⁴³. However, in this previous 364 365 study motoric cognitive risk instead of polypharmacy / AD-PRS was the main 366 predictor and Wave 3 was the baseline. Both here and in Mullin et al (2023)⁴³ 367 these covariates had a non-significant effect on dementia risk.

368 The results for the "general" polypharmacy Cox PH model are presented in the 369 Figure 1 forest plot. Only the APOE ε 4 allele count significantly increased – more 370 than tripled – the risk of incident dementia over the 17.5-year follow-up (HR = 3.28; 95% CI: 2.38 – 4.54; $p = 5.35 \times 10^{-13}$). Taking more drugs and having a high 371 372 PRS both increased the risk of incident dementia, however, the effects were not 373 significant. For number of drugs: HR = 1.04; 95% CI: 0.93 – 1.15; p = 0.517, and 374 for PRS: HR = 1.15; 95% CI: 0.85 - 1.55; p = 0.376. The interaction effect 375 between the number of drugs and PRS was in the direction of increased

376 dementia risk above that of their separate effects but was non-significant (HR =

377 1.06; 95% CI: 0.98 - 1.15; p = 0.135).

Predictor		N	Events	Hazard ratio	HR (95% CI)	p-value
sex	male	391	53		Reference	
	female	368	52	- 	1.05 (0.70, 1.57)	0.810
SIMD index		759			0.96 (0.77, 1.18)	0.680
APOE e4 count		759			→ 3.28 (2.38, 4.54)	<1e-04
age (years)		759		- -	1.21 (0.94, 1.56)	0.147
BMI		759		#	1.04 (0.99, 1.08)	0.114
smoker	never	367	54		Reference	
	ex	328	43 •	- •	1.00 (0.66, 1.53)	0.985
	current	64	8		1.72 (0.80, 3.68)	0.166
drinks alcohol	no	98	11		Reference	
	yes	661	94 +		1.23 (0.64, 2.36)	0.538
comorbidities idx		759		- # -	0.96 (0.83, 1.12)	0.619
no. of drugs		759		+	1.04 (0.93, 1.15)	0.517
PRS		759		;∎	1.15 (0.85, 1.55)	0.376
no. of drugs * PRS		759			1.06 (0.98, 1.15)	0,135

All-cause Dementia

Figure 1: Forest plot showing the Cox PH model Hazard Ratios for each predictor's association with all-cause incident dementia. The "no. of drugs" predictor includes all drugs taken by an individual after data cleaning. HR for Genomic Principal Components are not shown for illustration purposes, but were included in the model. The forest plot was produced using the "forestmodel" R package. HR: Hazard Ratio; CI: Confidence Interval; PRS: Polygenic Risk Score; BMI: Body Mass Index; SIMD: Scottish Index of Multiple Deprivation.

384

Figure 2 presents the association results for the Cox PH model that includes the "nervous system active" polypharmacy predictor. The *APOE* ϵ 4 predictor is, again, a highly significant risk factor (HR = 3.36; 95% CI: 2.43 - 4.65); p = 2.63x10⁻¹³). This time, however, the number of nervous system active drugs significantly increased the follow-up dementia risk (HR = 1.37; 95% CI: 1.02 -1.84; p = 0.035). The positive effect of the PRS was, now, also significant (HR = 1.42; 95% CI: 1.10 - 1.82; p = 0.006). The interaction between the number of

nervous system active drugs and the PRS, however, had a non-significant negative effect (HR = 0.95; 95% CI: 0.72 - 1.25; p = 0.707).

394

395

Predictor		N	Events	Hazard ratio	HR (95% CI)	p-value
sex	male	391	53		Reference	P
	female	368	52		1.04 (0.70, 1.54)	0.857
SIMD index		759		- -	0.95 (0.77, 1.18)	0.662
APOE e4 count		759			→ 3.36 (2.43, 4.65)	<1e-04
age (years)		759			1.19 (0.92, 1.54)	0.185
ВМІ		759		*	1.03 (0.99, 1.08)	0.158
smoker	never	367	54		Reference	
	ex	328	43		0.96 (0.63, 1.46)	0.856
	current	64	8		1.69 (0.79, 3.63)	0.178
drinks alcohol	no	98	11		Reference	
	yes	661	94	·	1.32 (0.69, 2.53)	0.399
comorbidities idx		759			0.96 (0.84, 1.09)	0.511
no. of NS-active drugs		759			1.37 (1.02, 1.84)	0.035
PRS		759		- -	1.42 (1.10, 1.82)	0.006
no. of NS-active drugs * PRS		759			0.95 (0.72, 1.25)	0.707

All-cause Dementia ('NS-active' polypharmacy predictor)

Figure 2: Forest plot showing the Cox PH model Hazard Ratios for each predictor's association with all-cause incident dementia. The "no. of NS-active drugs" predictor includes drugs acting on the nervous system taken by an individual. HR for Genomic Principal Components are not shown for illustration purposes, but were included in the model. The forest plot was produced using the "forestmodel" R package. HR: Hazard Ratio; CI: Confidence Interval; PRS: Polygenic Risk Score; BMI: Body Mass Index; SIMD: Scottish Index of Multiple Deprivation; NS-active: nervous systemactive.

403

The main results of the Fine – Grey competing risk regression models, adjusting for mortality as a competing risk of dementia, are presented in Figure 3. Models were run for both the "general" polypharmacy predictor and the "nervous systemactive" polypharmacy, and their interaction with PRS, adjusting for the full set of

408 covariates. Results for the full list of covariates are presented in Sup. Figure 4. 409 For the "general" polypharmacy model, the results were similar to the unadjusted model, with only the APOE ε 4 predictor having a significant effect (HR = 3.38; 410 95% CI: 2.46 - 4.66; $p = 8.0 \times 10^{-14}$). "General" polypharmacy, PRS and their 411 interaction all have small, positive, non-significant association with incident 412 413 dementia, after adjusting for the risk of death (Figure 3, top). Regarding the 414 "nervous system-active" polypharmacy model, the PRS genetic effect remained 415 significant after accounting for death (HR = 1.42; 95% CI: 1.13 - 1.78; p = 416 0.0029), but the "nervous system-active" polypharmacy predictor marginally lost 417 significance (HR = 1.27; 95% CI: 0.98 – 1.65; p = 0.068). The PRS * "ns-active" 418 polypharmacy interaction was again nonsignificant (HR = 0.98; 95% CI: 0.78 -419 1.23; p = 0.86) (Figure 3, bottom).

Because the interaction term was nonsignificant in both models, the mortality adjusted models were re-run omitting this term. Results showed that PRS had a significant positive effect on dementia risk in both general and NS-active polypharmacy models: HR(general) = 1.39; 95% CI: 1.15-1.67; p<0.001 and HR(NS-active) = 1.40; 95% CI: 1.16-1.69; p-value<0.001 respectively; and that polypharmacy effects were nonsignificant (Sup. Figure 5).

Using AD instead of all-cause dementia as outcome did not meaningfully alter the
results of either the "general" or the "nervous system-active" polypharmacy
models (Sup. Figure 6 and Sup. Figure 7 for AD-specific Cox PH models and
Sup. Figure 8 for AD-specific competing risk regression models).

430

431

432

433



435 Figure 3: Forest plot showing the Competing Risk Regression models' Hazard Ratios for the 436 association with all-cause incident dementia, adjusting for death as a competing risk. Only 437 predictors of interest are shown here for illustration purposes, but the full set of predictors were 438 included in the models. Upper figure shows the results for the model using the "general" 439 polypharmacy variable (no. of drugs), whereas lower figure shows the results for the nervous-440 system active no. of drugs. The "Estimates" of the forest plot are Hazard Ratios (HR). CRR: 441 Competing Risk Regression; UCI: Upper Confidence Interval; LCI: Lower Confidence Interval; 442 PRS: Polygenic Risk Score; NS-active: nervous system-active. The forest plot was produced 443 using the "forest" R package.

444

445 4 DISCUSSION

446 **4.1 Interpretation of findings**

447 This is the first study to assess the interaction between polypharmacy and 448 dementia polygenic risk in shaping all-cause dementia risk. Here, higher 449 polypharmacy exposure, higher polygenic risk (PRS), and their interaction were 450 positively associated with increased dementia risk although only PRS was 451 significant when main effects were considered. The positive direction of effect for 452 the interaction between general polypharmacy and PRS is consistent with our 453 hypothesis that the adverse effects of polypharmacy are modulated by adverse 454 genetic effects which increases the risk of dementia over and above their 455 separate effects. However, the nervous system acting polypharmacy interaction 456 with genetic score had an almost zero non-significant effect. It is possible that the 457 low variability of the predictor (only 9 people with 3 or more nervous system active medications) decreased accurate inferences. 458

459 Adjusting for death as a competing risk did not substantially change results, 460 indicating that mortality did not affect the association between predictors and 461 dementia. This was unexpected, given the high number of deaths in the sample: 462 277 people in total and 220 people without dementia that could be potential 463 patients otherwise. In these models, and omitting the nonsignificant 464 polypharmacy x PRS interaction effect, the polygenic effect was significant in the 465 hypothesised direction of increased dementia risk. General and NS-active 466 polypharmacy main effects did not alter the risk of dementia, although the latter 467 effect had a larger HR which approached significance indicating potential differences between types of medication used. In previous studies, PRS and 468 polypharmacy have been often associated with dementia risk⁵¹, but they had not 469 been modelled together. Our finding of non-significant polypharmacy effects 470

471 when controlling for AD polygenic risk might indicate that the previously reported 472 polypharmacy effect on dementia is confounded by polygenic risk for the disease. However, this hypothesis may be difficult to prove using PRS. Here low 473 correlation of AD-PRS with polypharmacy was observed (Pearson's r=0.041), 474 and, overall, polygenic scores for complex diseases explain little variation of 475 drug-related phenotypes⁵². APOE status is frequently used as a proxy covariate 476 for genetic susceptibility in studies of polypharmacy effects on dementia^{28,53}, with 477 polypharmacy regimes remaining significantly predictive of dementia risk after 478 adjusting for APOE status²⁸. One study found that polypharmacy lost significance 479 480 after adjusting for APOE in a population of Aboriginal Australians⁵⁴, although the 481 polypharmacy effect size remained similar with its unadjusted value. Larger longitudinal studies of people with both low and high dementia polygenic risk and 482 483 low and high polypharmacy use are needed to clarify the role of genetic 484 confounding on polypharmacy effects.

485 The APOE gene was the only other covariate that had a significant effect on 486 dementia. This was expected, given its strong and well established role in dementia and AD pathogenesis⁸. Other well established risk factors did not have 487 488 a significant effect on dementia: BMI, alcohol intake, smoking, and deprivation 489 index, although their effects' direction was expected¹. Inadequate sample size is 490 again a plausible explanation, coupled with restrictions of range in the variables 491 stemming from selection bias in the LBC1936: participants are healthier and from higher socioeconomic status than the general population²⁹. 492

In future, polypharmacy x polygenic interaction effects might be investigated with
 increased pathway specificity. For example, PRS calculated using only SNPs

495 pertaining to a certain biological pathway (e.g. synaptic processes)¹². Testing 496 whether sub-categories of polypharmacy measurements, such as the nervous 497 system specific polypharmacy predictor, mask the effects of nervous system 498 related pathway-specific PRS could shed light on whether those pathways are 499 modulated by specific drugs. An important caveat, however, is that the predictive 500 ability of pathway-specific PRS are potentially smaller than the genome-wide 501 PRS, so it would be necessary to use large sufficiently powered samples¹².

502 Furthermore, when studying polypharmacy, a direct interpretation of associations with outcomes is difficult as confounding by indication may be present^{28,55}. This 503 504 means that dementia may be caused not because of polypharmacy, but due to 505 the comorbidities for which multiple drugs are taken. This can affect both the 506 effects of polypharmacy exposure and the polypharmacy interaction with PRS. 507 However, in the present study, the comorbidities index covariate was not 508 significant and had negligible effect, indicating that the presence of comorbid health conditions did not affect dementia risk. This could be again arising due to 509 small sample size, as per previous similar studies in LBC1936⁴³. It could be 510 511 informative to include separate health conditions that are established dementia 512 risk factors as covariates (e.g., depression, diabetes, and hypertension) and not 513 as part of the comorbidities index covariate. Then, again, small sample size would not allow for the excessive use of covariates, due to the risk of overfitting. 514

515 **4.2 Strengths and limitations**

516 Several strengths can be identified for the present analysis. First, the high 517 accuracy of the dementia ascertainment outcomes, being based on Electronic 518 Health Records, clinical assessments and expert consensus⁴². This increases the

519 power to detect true associations with dementia risk, compared to non-curated 520 dementia diagnoses. Secondly, the LBC1936 study design provides an appropriate dataset to study dementia, due to the older age of the participants 521 522 (average of 69.5 years on baseline), extensive follow-up period (up to 17.5 years) 523 and absence of dementia at baseline, allowing for the investigation of risk factors 524 early on during disease development. Thirdly, LBC1936's thorough medication 525 recording protocol, allowing the inclusion of both prescribed and over-the-counter 526 medications in the polypharmacy predictors provides a more accurate picture of 527 the medication state of the individuals. In other studies where polypharmacy is modelled, only prescribed drugs are included^{25,28}, which may underestimate the 528 529 true polypharmacy burden.

530 On the other hand, several limitations should be acknowledged. The major 531 limitation of the study is the low sample size. Detecting genotype by environment 532 interactions requires very large sample sizes, given their postulated small effect sizes³. Additionally, the definition of polypharmacy as the number of (systemic or 533 534 nervous system acting) drugs taken at a certain time point (Wave 1 testing) is not 535 optimal, as it lacks information on the duration of exposure and adherence to the medication. A better metric would be the number of daily drugs taken²¹ and the 536 537 time period, however no such information was available. Electronic Health 538 Records data may allow for such modelling. Finally, only baseline (Wave 1) 539 information for all predictors was used (polypharmacy, covariates). Cumulatively 540 incorporating the changes in the predictors over time until dementia diagnosis 541 would improve the power to detect true associations. That is, using information from later waves to construct time-varying predictor variables in the Cox PH 542

543 models is a sensible future direction for better delineating polypharmacy 544 trajectories.

545

546 **5 CONCLUSIONS**

547 In summary, in the present analysis it was hypothesised that the detrimental 548 effect of polypharmacy on dementia is modulated by one's genetic profile, with 549 high genetic risk exacerbating adverse polypharmacy effects. This interaction 550 effect was not supported for general polypharmacy or nervous system acting 551 polypharmacy. AD polygenic scores were associated with increased risk of 552 dementia, and there was suggestion that nervous system active drugs had 553 independent polypharmacy effects on dementia risk. Better characterising how 554 polypharmacy exerts adverse effects on individuals with high or low dementia 555 genetic risk may point towards supporting the case for de-prescribing 556 inappropriate medications in older adults dependent on one's genetic risk 557 towards dementia.

558

559 **ACKNOWLEDGEMENTS**

560 We are thankful to Dr. Sarah Harris and Dr. Jure Mur for the insightful 561 discussions on various topics of the project and LBC1936, and to Paul Redmond 562 and Dr. Gail Davies for guidance and assistance on data access.

563 This research was funded by the Legal & General Group (research grant to 564 establish the independent Advanced Care Research Centre at University of

565 Edinburgh). The funder had no role in conduct of the study, interpretation or the 566 decision to submit for publication. The views expressed are those of the authors 567 and not necessarily those of Legal & General. The LBC1936 study is supported 568 by the Biotechnology and Biological Sciences Research Council (BBSRC) and the ESRC (BB/W008793/1), Age UK (Disconnected Mind project), the Milton 569 570 Damerel Trust, and the University of Edinburgh. SRC was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal 571 572 Society (221890/Z/20/Z). The Lothian Birth Cohort 1936 study acknowledges the 573 financial support of NHS Research Scotland (NRS), through Edinburgh Clinical 574 Research Facility. We gratefully acknowledge the contributions of the LBC1936 575 participants and members of the LBC1936 research team who collect and 576 manage the LBC data.

578

579 **REFERENCES**

- Lourida I, Hannon E, Littlejohns TJ, et al. Association of Lifestyle and Genetic Risk With
 Incidence of Dementia. *JAMA*. 2019;322(5):430. doi:10.1001/jama.2019.9879
- Dunn AR, O'Connell KMS, Kaczorowski CC. Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease. *Neuroscience & Biobehavioral Reviews*. 2019;103:73-80. doi:10.1016/j.neubiorev.2019.06.018
- Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and
 biomarkers. *Biochemical Pharmacology*. 2014;88(4):640-651. doi:10.1016/j.bcp.2013.12.024

⁵⁷⁷ All authors declare no competing interests.

Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024
 report of the Lancet standing Commission. *The Lancet*. 2024;404(10452):572-628.
 doi:10.1016/S0140-6736(24)01296-0

^{591 5.} Bellenguez C. New insights into the genetic etiology of Alzheimer's disease and related 592 dementias. *Nature Genetics*. 2022;54.

593 594 595 596 597	6.	Alzheimer Disease Genetics Consortium (ADGC), The European Alzheimer's Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. <i>Nat Genet</i> . 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2
598 599	7.	Gatz M, Reynolds CA, Fratiglioni L, et al. Role of Genes and Environments for Explaining Alzheimer Disease. <i>Arch Gen Psychiatry</i> . 2006;63(2):168. doi:10.1001/archpsyc.63.2.168
600 601	8.	Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. <i>Nat Rev Neurol</i> . 2013;9(2):106-118. doi:10.1038/nrneurol.2012.263
602 603 604	9.	Gharbi-Meliani A, Dugravot A, Sabia S, et al. The association of APOE ɛ4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study. <i>Alz Res Therapy</i> . 2021;13(1):5. doi:10.1186/s13195-020-00740-0
605 606 607	10.	Ware EB, Faul JD, Mitchell CM, Bakulski KM. Considering the APOE locus in Alzheimer's disease polygenic scores in the Health and Retirement Study: a longitudinal panel study. BMC Med Genomics. 2020;13(1):164. doi:10.1186/s12920-020-00815-9
608 609 610	11.	Leonenko G, Baker E, Stevenson-Hoare J, et al. Identifying individuals with high risk of Alzheimer's disease using polygenic risk scores. <i>Nat Commun</i> . 2021;12(1):4506. doi:10.1038/s41467-021-24082-z
611 612 613	12.	Harrison JR, Mistry S, Muskett N, Escott-Price V. From Polygenic Scores to Precision Medicine in Alzheimer's Disease: A Systematic Review. Brookes K, ed. <i>JAD</i> . 2020;74(4):1271- 1283. doi:10.3233/JAD-191233
614 615 616	13.	Seto M, Weiner RL, Dumitrescu L, Hohman TJ. Protective genes and pathways in Alzheimer's disease: moving towards precision interventions. <i>Mol Neurodegeneration</i> . 2021;16(1):29. doi:10.1186/s13024-021-00452-5
617 618	14.	Choi SW, Mak TSH, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759-2772. doi:10.1038/s41596-020-0353-1
619 620 621	15.	Jin X, Shu C, Zeng Y, Liang L, Ji JS. Interaction of greenness and polygenic risk score of Alzheimer's disease on risk of cognitive impairment. <i>Science of The Total Environment</i> . 2021;796:148767. doi:10.1016/j.scitotenv.2021.148767
622 623 624	16.	Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without <i>APOE</i> ɛ4. <i>Neurology</i> . 2005;65(9):1409-1414. doi:10.1212/01.wnl.0000183148.34197.2e
625 626 627	17.	Licher S, Ahmad S, Karamujić-Čomić H, et al. Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population. <i>Nat Med</i> . 2019;25(9):1364- 1369. doi:10.1038/s41591-019-0547-7
628 629 630	18.	Kivipelto M, Rovio S, Ngandu T, et al. Apolipoprotein E ⊠4 magnifies lifestyle risks for dementia: a population-based study. <i>Journal of Cellular and Molecular Medicine</i> . 2008;12(6b):2762-2771. doi:10.1111/j.1582-4934.2008.00296.x

631 632 633	19.	Solomon A, Turunen H, Ngandu T, et al. Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial. <i>JAMA Neurol</i> . 2018;75(4):462. doi:10.1001/jamaneurol.2017.4365
634 635 636	20.	Rovio S, Kåreholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. <i>The Lancet Neurology</i> . 2005;4(11):705-711. doi:10.1016/S1474-4422(05)70198-8
637 638	21.	Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. <i>BMC Geriatr</i> . 2017;17(1):230. doi:10.1186/s12877-017-0621-2
639 640	22.	Esumi S, Ushio S, Zamami Y. Polypharmacy in Older Adults with Alzheimer's Disease. <i>Medicina</i> . 2022;58(10):1445. doi:10.3390/medicina58101445
641 642 643	23.	Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health Outcomes Associated with Polypharmacy in Community-Dwelling Older Adults: A Systematic Review. J Am Geriatr Soc. 2014;62(12):2261-2272. doi:10.1111/jgs.13153
644 645	24.	Bushardt R. Polypharmacy: Misleading, but manageable. <i>CIA</i> . 2008;Volume 3:383-389. doi:10.2147/CIA.S2468
646 647 648	25.	Park HY, Park JW, Song HJ, Sohn HS, Kwon JW. The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea. Laks J, ed. <i>PLoS ONE</i> . 2017;12(1):e0169463. doi:10.1371/journal.pone.0169463
649 650 651 652	26.	Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data. <i>Age Ageing</i> . Published online October 13, 2016:ageing;afw176v1. doi:10.1093/ageing/afw176
653 654 655	27.	Mueller C, Molokhia M, Perera G, et al. Polypharmacy in people with dementia: Associations with adverse health outcomes. <i>Experimental Gerontology</i> . 2018;106:240-245. doi:10.1016/j.exger.2018.02.011
656 657 658	28.	Mur J, Russ TC, Cox SR, Marioni RE, Muniz-Terrera G. Association between anticholinergic burden and dementia in UK Biobank. <i>A&D Transl Res & Clin Inter</i> v. 2022;8(1):e12290. doi:10.1002/trc2.12290
659 660	29.	Taylor AM, Pattie A, Deary IJ. Cohort Profile Update: The Lothian Birth Cohorts of 1921 and 1936. International Journal of Epidemiology. 2018;47(4):1042-1042r. doi:10.1093/ije/dyy022
661 662	30.	The Trend of Scottish Intelligence: A Comparison of the 1947 and 1932 Surveys of the Intelligence of Eleven-Year-Old Pupils. University London Press; 1949:xxviii, 151.
663 664 665 666	31.	Deary IJ, Whalley LJ, Starr JM. A lifetime of intelligence: Follow-up studies of the Scottish mental surveys of 1932 and 1947. <i>A lifetime of intelligence: Follow-up studies of the Scottish</i> <i>mental surveys of 1932 and 1947</i> . Published online 2009:xvi, 285-xvi, 285. doi:10.1037/11857-000
667 668	32.	Deary IJ, Gow AJ, Pattie A, Starr JM. Cohort Profile: The Lothian Birth Cohorts of 1921 and 1936. International Journal of Epidemiology. 2012;41(6):1576-1584. doi:10.1093/ije/dyr197

669 670 671	33.	Houlihan LM, Davies G, Tenesa A, et al. Common Variants of Large Effect in F12, KNG1, and HRG Are Associated with Activated Partial Thromboplastin Time. <i>The American Journal of Human Genetics</i> . 2010;86(4):626-631. doi:10.1016/j.ajhg.2010.02.016
672 673	34.	the Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype imputation. <i>Nat Genet</i> . 2016;48(10):1279-1283. doi:10.1038/ng.3643
674 675 676	35.	Weale ME. Quality Control for Genome-Wide Association Studies. In: Barnes MR, Breen G, eds. <i>Genetic Variation</i> . Vol 628. Methods in Molecular Biology. Humana Press; 2010:341-372. doi:10.1007/978-1-60327-367-1_19
677 678 679	36.	Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. <i>GigaSci</i> . 2015;4(1):7. doi:10.1186/s13742-015-0047-8
680	37.	Purcell SM, Chang CC. PLINK v1.9. www.cog-genomics.org/plink/1.9/
681 682	38.	Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. GigaScience. 2019;8(7):giz082. doi:10.1093/gigascience/giz082
683 684	39.	ATC/DDD Index 2023. WHO Collaborating Centre for Drug Statistics Methodology. Accessed January 7, 2023. https://www.whocc.no/atc_ddd_index/
685 686	40.	British National Formulary (BNF). National Institute for Health and Care Excellence (NICE). Accessed January 7, 2023. https://bnf.nice.org.uk/
687 688	41.	Uffelmann E, Huang QQ, Munung NS, et al. Genome-wide association studies. <i>Nat Rev</i> <i>Methods Primers</i> . 2021;1(1):59. doi:10.1038/s43586-021-00056-9
689 690 691	42.	Mullin DS, Stirland LE, Buchanan E, et al. Identifying dementia using medical data linkage in a longitudinal cohort study: Lothian Birth Cohort 1936. <i>BMC Psychiatry</i> . 2023;23(1):303. doi:10.1186/s12888-023-04797-7
692 693 694	43.	Mullin DS, Gadd D, Russ TC, Luciano M, Muniz-Terrera G. Motoric cognitive risk syndrome trajectories and incident dementia over 10 years. <i>Cerebral Circulation - Cognition and Behavior</i> . 2023;5:100178. doi:10.1016/j.cccb.2023.100178
695 696	44.	International Classification of Diseases, Eleventh Revision (ICD-11), World Health Organization (WHO) 2019/2021. https://icd.who.int/en
697 698	45.	Cox DR. Regression Models and Life-Tables. <i>Journal of the Royal Statistical Society Series B</i> (Methodological). 1972;34(2):187-220.
699 700	46.	Kalbfleisch JD, Schaubel DE. Fifty Years of the Cox Model. <i>Annu Rev Stat Appl.</i> 2023;10(1):1- 23. doi:10.1146/annurev-statistics-033021-014043
701 702	47.	Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. <i>Statistics in Medicine</i> . 2017;36(27):4391-4400. doi:10.1002/sim.7501
703 704 705	48.	Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association. 1999;94(446):496-509. doi:10.1080/01621459.1999.10474144

- 706 49. R Core Team. R: A language and environment for statistical computing. Published online
 707 2022. https://www.R-project.org/
- Therneau T. A Package for Survival Analysis in R. https://CRAN.R project.org/package=survival
- 51. Leelakanok N, D'Cunha RR. Association between polypharmacy and dementia A systematic
 review and metaanalysis. *Aging & Mental Health*. 2019;23(8):932-941.
 doi:10.1080/13607863.2018.1468411
- 52. Simona A, Song W, Bates DW, Samer CF. Polygenic risk scores in pharmacogenomics:
 opportunities and challenges—a mini review. *Front Genet*. 2023;14:1217049.
 doi:10.3389/fgene.2023.1217049
- 53. Gray SL, Anderson ML, Dublin S, et al. Cumulative Use of Strong Anticholinergics and
 Incident Dementia: A Prospective Cohort Study. *JAMA Intern Med*. 2015;175(3):401.
 doi:10.1001/jamainternmed.2014.7663
- 54. Lavrencic LM, Delbaere K, Broe GA, et al. Dementia Incidence, *APOE* Genotype, and Risk
 Factors for Cognitive Decline in Aboriginal Australians: A Longitudinal Cohort Study. *Neurology*. 2022;98(11). doi:10.1212/WNL.00000000013295
- 55. Kyriacou DN, Lewis RJ. Confounding by Indication in Clinical Research. JAMA.
 2016;316(17):1818. doi:10.1001/jama.2016.16435